<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938639</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-CAL-09-59</org_study_id>
    <nct_id>NCT00938639</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults</brief_title>
  <official_title>A Phase II, Single-centre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's Monovalent H1N1 Influenza Virus Vaccine in Healthy Adults Aged 18 to &lt; 65 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for
      eliciting an immune response to H1N1 influenza in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemagglutination Inhibition (HI) and Microneutralisation (MN) Antibody Titre Seroconversion Rate After the First Vaccination</measure>
    <time_frame>Before and 21 days after the first vaccination</time_frame>
    <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HI and MN Antibody Titre Seroconversion Rate After the Second Vaccination</measure>
    <time_frame>Before and 21 days after the second vaccination</time_frame>
    <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Increase (GMFI) in the HI and MN Antibody Titre After the First Vaccination</measure>
    <time_frame>Before and 21 days after the first vaccination</time_frame>
    <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMFI in the HI and MN Antibody Titer After the Second Vaccination</measure>
    <time_frame>Before and 21 days after the second vaccination</time_frame>
    <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the First Vaccination</measure>
    <time_frame>21 days after the first vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the Second Vaccination</measure>
    <time_frame>21 days after the second vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HI and MN Antibody Titre Seroconversion Rate After the First Vaccination by Age Group</measure>
    <time_frame>Before and 21 days after the first vaccination</time_frame>
    <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI and MN Antibody Titre Seroconversion Rate After the Second Vaccination by Age Group</measure>
    <time_frame>Before and 21 days after the second vaccination</time_frame>
    <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFI in the HI and MN Antibody Titre After the First Vaccination by Age Group</measure>
    <time_frame>Before and 21 days after the first vaccination</time_frame>
    <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFI in the HI and MN Antibody Titre After the Second Vaccination by Age Group</measure>
    <time_frame>Before and 21 days after the second vaccination</time_frame>
    <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the First Vaccination by Age Group</measure>
    <time_frame>21 days after the first vaccination</time_frame>
    <description>Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the Second Vaccination by Age Group</measure>
    <time_frame>21 days after the second vaccination</time_frame>
    <description>Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Baseline Titre Less Than 1:10 Achieving Seroconversion After Vaccination</measure>
    <time_frame>Before and 21 days after each vaccination</time_frame>
    <description>The number of participants with a baseline titre less than 1:10 differed according to antibody assay (HI or MN) and is shown in the category titles accordingly. The total number of participants analysed includes all evaluable participants; however, the analysis is stratified by baseline titre and those participants with a baseline titre less than 1:10 are presented in this outcome measure while those with a baseline titre of 1:10 or more are presented in a separate outcome measure.
Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Baseline Titre Greater Than or Equal to 1:10 Achieving Seroconversion After Vaccination</measure>
    <time_frame>Before and 21 days after each vaccination</time_frame>
    <description>The number of participants with a baseline titre greater than or equal to 1:10 differed according to antibody assay (HI or MN) and is shown in the category titles accordingly. The total number of participants analysed includes all evaluable participants; however, the analysis is stratified by baseline titre and those participants with a baseline titre of 1:10 or more are presented in this outcome measure while those with a baseline titre less than 1:10 are presented in a separate outcome measure.
Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre (ie, a significant increase in antibody titre after vaccination).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFI in the HI Antibody Titre 180 Days After the Second Vaccination</measure>
    <time_frame>21 days and 180 days after the second vaccination</time_frame>
    <description>The GMFI in antibody titre was calculated by taking the anti-logs of the means of the log transformed fold-increases in the antibody titre 180 days after the second vaccination over the antibody titre 21 days after the second vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More 180 Days After the Second Vaccination</measure>
    <time_frame>180 days after the second vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Solicited Local Adverse Events (AEs) After the First Vaccination</measure>
    <time_frame>From Day 0 to Day 6 after the first vaccination</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Size &gt; 100 mm for injection site redness, induration/swelling, and bruising.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Local AEs After the First Vaccination</measure>
    <time_frame>From Day 0 to Day 6 after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Solicited Local AEs After the Second Vaccination</measure>
    <time_frame>From Day 0 to Day 6 after the second vaccination</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Size &gt; 100 mm for injection site redness, induration/swelling, and bruising.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Local AEs After the Second Vaccination</measure>
    <time_frame>From Day 0 to Day 6 after the second vaccination and up to Day 20 after the second vaccination if AE is ongoing at Day 7</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Solicited Systemic AEs After the First Vaccination</measure>
    <time_frame>From Day 0 to Day 6 after the first vaccination</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Temperature 102.2°F (39.0°C) or more for fevers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Systemic AEs After the First Vaccination</measure>
    <time_frame>From Day 0 to Day 6 after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Solicited Systemic AEs After the Second Vaccination</measure>
    <time_frame>From Day 0 to Day 6 after the second vaccination</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Temperature 102.2°F (39.0°C) or more for fevers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Solicited Systemic AEs After the Second Vaccination</measure>
    <time_frame>From Day 0 to Day 6 after the second vaccination and up to Day 20 after the second vaccination if AE is ongoing at Day 7</time_frame>
    <description>Solicited AEs included AEs that were specifically sought for.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and New Onset of Chronic Illnesses (NOCIs)</measure>
    <time_frame>Up to 180 days after the last vaccination</time_frame>
    <description>An AESI was defined as an AE for which the association with seasonal influenza vaccine was unclear. A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (eg, diabetes, asthma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Intensity of Unsolicited AEs</measure>
    <time_frame>From Day 0 to Day 20 after vaccination; up to 180 days after the last vaccination for SAEs, AESIs, and NOCIs</time_frame>
    <description>Unsolicited AEs included AEs other than those specifically sought for.
The grading definitions were:
Mild (Grade 1): Symptoms were easily tolerated and did not interfere with daily activities.
Moderate (Grade 2): Enough discomfort to cause some interference with daily activities.
Severe (Grade 3): Incapacitating, with inability to work or do usual activities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Influenza Caused by the Novel Influenza A (H1N1) Virus</condition>
  <arm_group>
    <arm_group_label>CSL425 (15 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL425 (30 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL425</intervention_name>
    <description>CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)</description>
    <arm_group_label>CSL425 (15 mcg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL425</intervention_name>
    <description>CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)</description>
    <arm_group_label>CSL425 (30 mcg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged &gt;= 18 to &lt; 65 years at the time of providing informed consent.

        Exclusion Criteria:

          -  Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to
             eggs, chicken protein, thiomersal, neomycin, polymyxin, or any components of the Study
             Vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, Vaccines Clinical Development</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <results_reference>
    <citation>Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009 Dec 17;361(25):2405-13. doi: 10.1056/NEJMoa0907413. Epub 2009 Sep 10.</citation>
    <PMID>19745216</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2009</study_first_posted>
  <results_first_submitted>July 24, 2013</results_first_submitted>
  <results_first_submitted_qc>October 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2013</results_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CSL425 (15 mcg)</title>
          <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
        </group>
        <group group_id="P2">
          <title>CSL425 (30 mcg)</title>
          <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Moved away from study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family issues</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CSL425 (15 mcg)</title>
          <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
        </group>
        <group group_id="B2">
          <title>CSL425 (30 mcg)</title>
          <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="15.12"/>
                    <measurement group_id="B2" value="42.9" spread="15.39"/>
                    <measurement group_id="B3" value="43.7" spread="15.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Haemagglutination Inhibition (HI) and Microneutralisation (MN) Antibody Titre Seroconversion Rate After the First Vaccination</title>
        <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
        <time_frame>Before and 21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Haemagglutination Inhibition (HI) and Microneutralisation (MN) Antibody Titre Seroconversion Rate After the First Vaccination</title>
          <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
          <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion rate - HI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" lower_limit="65.4" upper_limit="81.7"/>
                    <measurement group_id="O2" value="81.5" lower_limit="73.4" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion rate - MN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="69.0" upper_limit="84.6"/>
                    <measurement group_id="O2" value="75.6" lower_limit="66.9" upper_limit="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HI and MN Antibody Titre Seroconversion Rate After the Second Vaccination</title>
        <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
        <time_frame>Before and 21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>HI and MN Antibody Titre Seroconversion Rate After the Second Vaccination</title>
          <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
          <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion rate - HI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1" lower_limit="73.9" upper_limit="88.5"/>
                    <measurement group_id="O2" value="89.6" lower_limit="82.5" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion rate - MN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2" lower_limit="79.7" upper_limit="92.6"/>
                    <measurement group_id="O2" value="83.5" lower_limit="75.4" upper_limit="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Increase (GMFI) in the HI and MN Antibody Titre After the First Vaccination</title>
        <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
        <time_frame>Before and 21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Increase (GMFI) in the HI and MN Antibody Titre After the First Vaccination</title>
          <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
          <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>geometric mean fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMFI - HI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.83" lower_limit="8.91" upper_limit="15.70"/>
                    <measurement group_id="O2" value="19.54" lower_limit="14.58" upper_limit="26.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFI - MN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.83" lower_limit="17.56" upper_limit="35.11"/>
                    <measurement group_id="O2" value="39.70" lower_limit="26.68" upper_limit="59.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>GMFI in the HI and MN Antibody Titer After the Second Vaccination</title>
        <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
        <time_frame>Before and 21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in the HI and MN Antibody Titer After the Second Vaccination</title>
          <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
          <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>geometric mean fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMFI - HI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.00" lower_limit="12.36" upper_limit="20.71"/>
                    <measurement group_id="O2" value="23.30" lower_limit="17.92" upper_limit="30.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFI - MN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.30" lower_limit="23.96" upper_limit="43.54"/>
                    <measurement group_id="O2" value="46.50" lower_limit="32.83" upper_limit="65.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the First Vaccination</title>
        <time_frame>21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the First Vaccination</title>
          <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with HI titer ≥ 1:40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="89.4" upper_limit="98.1"/>
                    <measurement group_id="O2" value="89.1" lower_limit="82.0" upper_limit="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with MN titer ≥ 1:40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3" lower_limit="81.2" upper_limit="93.5"/>
                    <measurement group_id="O2" value="83.2" lower_limit="75.2" upper_limit="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the Second Vaccination</title>
        <time_frame>21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the Second Vaccination</title>
          <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with HI titer ≥ 1:40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="94.0" upper_limit="99.8"/>
                    <measurement group_id="O2" value="96.5" lower_limit="91.3" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with MN titer ≥ 1:40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="90.3" upper_limit="98.6"/>
                    <measurement group_id="O2" value="92.2" lower_limit="85.7" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI and MN Antibody Titre Seroconversion Rate After the First Vaccination by Age Group</title>
        <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
        <time_frame>Before and 21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg), Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (15 mcg), Older Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (30 mcg), Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg), Older Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>HI and MN Antibody Titre Seroconversion Rate After the First Vaccination by Age Group</title>
          <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
          <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion rate - HI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" lower_limit="64.7" upper_limit="87.5"/>
                    <measurement group_id="O2" value="71.0" lower_limit="58.1" upper_limit="81.8"/>
                    <measurement group_id="O3" value="85.2" lower_limit="73.8" upper_limit="93.0"/>
                    <measurement group_id="O4" value="77.6" lower_limit="64.7" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion rate - MN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="70.6" upper_limit="91.4"/>
                    <measurement group_id="O2" value="72.6" lower_limit="59.8" upper_limit="83.1"/>
                    <measurement group_id="O3" value="83.6" lower_limit="71.9" upper_limit="91.8"/>
                    <measurement group_id="O4" value="67.2" lower_limit="53.7" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI and MN Antibody Titre Seroconversion Rate After the Second Vaccination by Age Group</title>
        <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
        <time_frame>Before and 21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg), Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (15 mcg), Older Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (30 mcg), Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg), Older Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>HI and MN Antibody Titre Seroconversion Rate After the Second Vaccination by Age Group</title>
          <description>Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination antibody titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
          <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion rate - HI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" lower_limit="71.2" upper_limit="92.2"/>
                    <measurement group_id="O2" value="80.6" lower_limit="68.6" upper_limit="89.6"/>
                    <measurement group_id="O3" value="87.9" lower_limit="76.7" upper_limit="95.0"/>
                    <measurement group_id="O4" value="91.2" lower_limit="80.7" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion rate - MN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" lower_limit="77.8" upper_limit="95.9"/>
                    <measurement group_id="O2" value="85.5" lower_limit="74.2" upper_limit="93.1"/>
                    <measurement group_id="O3" value="86.2" lower_limit="74.6" upper_limit="93.9"/>
                    <measurement group_id="O4" value="80.7" lower_limit="68.1" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFI in the HI and MN Antibody Titre After the First Vaccination by Age Group</title>
        <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
        <time_frame>Before and 21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg), Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (15 mcg), Older Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (30 mcg), Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg), Older Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in the HI and MN Antibody Titre After the First Vaccination by Age Group</title>
          <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
          <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>geometric mean fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMFI - HI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.13" lower_limit="9.97" upper_limit="22.96"/>
                    <measurement group_id="O2" value="9.39" lower_limit="6.37" upper_limit="13.84"/>
                    <measurement group_id="O3" value="25.79" lower_limit="17.00" upper_limit="39.11"/>
                    <measurement group_id="O4" value="14.60" lower_limit="9.68" upper_limit="22.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFI - MN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.73" lower_limit="22.23" upper_limit="60.68"/>
                    <measurement group_id="O2" value="17.21" lower_limit="10.72" upper_limit="27.64"/>
                    <measurement group_id="O3" value="54.91" lower_limit="31.75" upper_limit="94.96"/>
                    <measurement group_id="O4" value="28.22" lower_limit="15.80" upper_limit="50.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFI in the HI and MN Antibody Titre After the Second Vaccination by Age Group</title>
        <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
        <time_frame>Before and 21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg), Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (15 mcg), Older Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (30 mcg), Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg), Older Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in the HI and MN Antibody Titre After the Second Vaccination by Age Group</title>
          <description>GMFI in antibody titre was defined as the geometric mean of the fold increase in the post-vaccination antibody titre over the pre-vaccination antibody titre.
Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
          <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>geometric mean fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMFI - HI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.00" lower_limit="12.17" upper_limit="26.62"/>
                    <measurement group_id="O2" value="14.41" lower_limit="10.16" upper_limit="20.45"/>
                    <measurement group_id="O3" value="26.01" lower_limit="17.69" upper_limit="38.25"/>
                    <measurement group_id="O4" value="20.82" lower_limit="14.44" upper_limit="30.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFI - MN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.95" lower_limit="23.39" upper_limit="61.58"/>
                    <measurement group_id="O2" value="28.00" lower_limit="19.26" upper_limit="40.70"/>
                    <measurement group_id="O3" value="55.79" lower_limit="33.51" upper_limit="92.90"/>
                    <measurement group_id="O4" value="38.63" lower_limit="23.79" upper_limit="62.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the First Vaccination by Age Group</title>
        <description>Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
        <time_frame>21 days after the first vaccination</time_frame>
        <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg), Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (15 mcg), Older Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (30 mcg), Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg), Older Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the First Vaccination by Age Group</title>
          <description>Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
          <population>The Evaluable Population (for the first vaccination) comprised all randomised participants who received the first study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with HI titer ≥ 1:40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="88.1" upper_limit="99.6"/>
                    <measurement group_id="O2" value="93.5" lower_limit="84.3" upper_limit="98.2"/>
                    <measurement group_id="O3" value="98.4" lower_limit="91.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="79.3" lower_limit="66.6" upper_limit="88.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with MN titer ≥ 1:40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" lower_limit="85.6" upper_limit="98.9"/>
                    <measurement group_id="O2" value="82.3" lower_limit="70.5" upper_limit="90.8"/>
                    <measurement group_id="O3" value="95.1" lower_limit="86.3" upper_limit="99.0"/>
                    <measurement group_id="O4" value="70.7" lower_limit="57.3" upper_limit="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the Second Vaccination by Age Group</title>
        <description>Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
        <time_frame>21 days after the second vaccination</time_frame>
        <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg), Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (15 mcg), Older Adult</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O3">
            <title>CSL425 (30 mcg), Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O4">
            <title>CSL425 (30 mcg), Older Adult</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a HI or MN Antibody Titre of 1:40 or More After the Second Vaccination by Age Group</title>
          <description>Adults were aged from 18 to 49 years; Older adults were aged from 50 to 64 years.</description>
          <population>The Evaluable Population (for the second vaccination) comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with HI titer ≥ 1:40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="90.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.4" lower_limit="91.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="93.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="93.0" lower_limit="83.0" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with MN titer ≥ 1:40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="91.9" lower_limit="82.2" upper_limit="97.3"/>
                    <measurement group_id="O3" value="100.0" lower_limit="93.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="84.2" lower_limit="72.1" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Baseline Titre Less Than 1:10 Achieving Seroconversion After Vaccination</title>
        <description>The number of participants with a baseline titre less than 1:10 differed according to antibody assay (HI or MN) and is shown in the category titles accordingly. The total number of participants analysed includes all evaluable participants; however, the analysis is stratified by baseline titre and those participants with a baseline titre less than 1:10 are presented in this outcome measure while those with a baseline titre of 1:10 or more are presented in a separate outcome measure.
Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
        <time_frame>Before and 21 days after each vaccination</time_frame>
        <population>The Evaluable Population comprised all randomised participants who received the first (or second, as appropriate) study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Baseline Titre Less Than 1:10 Achieving Seroconversion After Vaccination</title>
          <description>The number of participants with a baseline titre less than 1:10 differed according to antibody assay (HI or MN) and is shown in the category titles accordingly. The total number of participants analysed includes all evaluable participants; however, the analysis is stratified by baseline titre and those participants with a baseline titre less than 1:10 are presented in this outcome measure while those with a baseline titre of 1:10 or more are presented in a separate outcome measure.
Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre.</description>
          <population>The Evaluable Population comprised all randomised participants who received the first (or second, as appropriate) study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After the first vaccination - HI (N = 42, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="80.5" upper_limit="98.5"/>
                    <measurement group_id="O2" value="83.7" lower_limit="70.3" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After the second vaccination - HI (N = 42, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2" lower_limit="83.8" upper_limit="99.4"/>
                    <measurement group_id="O2" value="93.6" lower_limit="82.5" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After the first vaccination - MN (N = 62, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" lower_limit="65.0" upper_limit="87.1"/>
                    <measurement group_id="O2" value="74.0" lower_limit="62.4" upper_limit="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After the second vaccination - MN (N = 60, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="81.6" upper_limit="97.2"/>
                    <measurement group_id="O2" value="87.3" lower_limit="77.3" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Baseline Titre Greater Than or Equal to 1:10 Achieving Seroconversion After Vaccination</title>
        <description>The number of participants with a baseline titre greater than or equal to 1:10 differed according to antibody assay (HI or MN) and is shown in the category titles accordingly. The total number of participants analysed includes all evaluable participants; however, the analysis is stratified by baseline titre and those participants with a baseline titre of 1:10 or more are presented in this outcome measure while those with a baseline titre less than 1:10 are presented in a separate outcome measure.
Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre (ie, a significant increase in antibody titre after vaccination).</description>
        <time_frame>Before and 21 days after each vaccination</time_frame>
        <population>The Evaluable Population comprised all randomised participants who received the study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Baseline Titre Greater Than or Equal to 1:10 Achieving Seroconversion After Vaccination</title>
          <description>The number of participants with a baseline titre greater than or equal to 1:10 differed according to antibody assay (HI or MN) and is shown in the category titles accordingly. The total number of participants analysed includes all evaluable participants; however, the analysis is stratified by baseline titre and those participants with a baseline titre of 1:10 or more are presented in this outcome measure while those with a baseline titre less than 1:10 are presented in a separate outcome measure.
Antibody titre seroconversion was defined as participants with a pre-vaccination titre of less than 1:10 achieving a post-vaccination titre of 1:40 or more; or participants with a pre-vaccination titre of 1:10 or more achieving a four-fold or greater increase in post-vaccination HI titre (ie, a significant increase in antibody titre after vaccination).</description>
          <population>The Evaluable Population comprised all randomised participants who received the study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After the first vaccination - HI (N = 78, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" lower_limit="52.4" upper_limit="74.7"/>
                    <measurement group_id="O2" value="80.0" lower_limit="68.7" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After the second vaccination - HI (N = 75, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" lower_limit="63.3" upper_limit="84.0"/>
                    <measurement group_id="O2" value="86.8" lower_limit="76.4" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After the first vaccination - MN (N = 58, 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" lower_limit="64.7" upper_limit="87.5"/>
                    <measurement group_id="O2" value="78.3" lower_limit="63.6" upper_limit="89.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After the second vaccination - MN (N = 57, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="70.1" upper_limit="91.3"/>
                    <measurement group_id="O2" value="77.3" lower_limit="62.2" upper_limit="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFI in the HI Antibody Titre 180 Days After the Second Vaccination</title>
        <description>The GMFI in antibody titre was calculated by taking the anti-logs of the means of the log transformed fold-increases in the antibody titre 180 days after the second vaccination over the antibody titre 21 days after the second vaccination.</description>
        <time_frame>21 days and 180 days after the second vaccination</time_frame>
        <population>The Evaluable Population comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>GMFI in the HI Antibody Titre 180 Days After the Second Vaccination</title>
          <description>The GMFI in antibody titre was calculated by taking the anti-logs of the means of the log transformed fold-increases in the antibody titre 180 days after the second vaccination over the antibody titre 21 days after the second vaccination.</description>
          <population>The Evaluable Population comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>geometric mean fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="0.44" upper_limit="0.55"/>
                    <measurement group_id="O2" value="0.42" lower_limit="0.38" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More 180 Days After the Second Vaccination</title>
        <time_frame>180 days after the second vaccination</time_frame>
        <population>The Evaluable Population comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a HI Antibody Titre of 1:40 or More 180 Days After the Second Vaccination</title>
          <population>The Evaluable Population comprised all randomised participants who received the second study vaccination; provided both pre- and post-vaccination blood samples; were not excluded from analyses (eg, for the use of a prohibited medication or a laboratory-confirmed 2009 H1N1 infection between Visit 1 and Visit 3).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="90.1" upper_limit="98.6"/>
                    <measurement group_id="O2" value="91.9" lower_limit="85.2" upper_limit="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Solicited Local Adverse Events (AEs) After the First Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Size &gt; 100 mm for injection site redness, induration/swelling, and bruising.</description>
        <time_frame>From Day 0 to Day 6 after the first vaccination</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Solicited Local Adverse Events (AEs) After the First Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Size &gt; 100 mm for injection site redness, induration/swelling, and bruising.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any tenderness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 tenderness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bruising at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 bruising at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Local AEs After the First Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for.</description>
        <time_frame>From Day 0 to Day 6 after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Local AEs After the First Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="2.423"/>
                    <measurement group_id="O2" value="1.67" spread="1.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00">Only one participant experienced redness at the injection site so the standard deviation cannot be derived</measurement>
                    <measurement group_id="O2" value="1.00">Only one participant experienced redness at the injection site so the standard deviation cannot be derived</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.809"/>
                    <measurement group_id="O2" value="2.70" spread="2.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="1.862"/>
                    <measurement group_id="O2" value="1.88" spread="1.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.83" spread="6.113"/>
                    <measurement group_id="O2" value="4.40" spread="7.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Solicited Local AEs After the Second Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Size &gt; 100 mm for injection site redness, induration/swelling, and bruising.</description>
        <time_frame>From Day 0 to Day 6 after the second vaccination</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Solicited Local AEs After the Second Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Size &gt; 100 mm for injection site redness, induration/swelling, and bruising.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any tenderness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 tenderness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bruising at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 bruising at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Local AEs After the Second Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for.</description>
        <time_frame>From Day 0 to Day 6 after the second vaccination and up to Day 20 after the second vaccination if AE is ongoing at Day 7</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Local AEs After the Second Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.519"/>
                    <measurement group_id="O2" value="2.40" spread="4.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="5.657"/>
                    <measurement group_id="O2" value="1.67" spread="1.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling/induration at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.500"/>
                    <measurement group_id="O2" value="1.43" spread="0.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.852"/>
                    <measurement group_id="O2" value="2.11" spread="1.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising at injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="5.196"/>
                    <measurement group_id="O2" value="2.00" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Solicited Systemic AEs After the First Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Temperature 102.2°F (39.0°C) or more for fevers.</description>
        <time_frame>From Day 0 to Day 6 after the first vaccination</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Solicited Systemic AEs After the First Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Temperature 102.2°F (39.0°C) or more for fevers.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise/feeling generally unwell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise/feeling generally unwell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any muscle ache (myalgia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8"/>
                    <measurement group_id="O2" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 muscle ache (myalgia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Systemic AEs After the First Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for.</description>
        <time_frame>From Day 0 to Day 6 after the first vaccination and up to Day 20 after the first vaccination if AE is ongoing at Day 7</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Systemic AEs After the First Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.432"/>
                    <measurement group_id="O2" value="1.64" spread="1.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise/feeling generally unwell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.328"/>
                    <measurement group_id="O2" value="1.47" spread="1.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle ache (myalgia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="1.729"/>
                    <measurement group_id="O2" value="1.67" spread="1.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.707"/>
                    <measurement group_id="O2" value="1.64" spread="1.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00">Only 1 participant experienced chills so the standard deviation cannot be derived.</measurement>
                    <measurement group_id="O2" value="1.38" spread="0.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in the CSL425 (15 mcg) group experienced vomiting after the first vaccination.</measurement>
                    <measurement group_id="O2" value="2.00" spread="1.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.378"/>
                    <measurement group_id="O2" value="1.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Solicited Systemic AEs After the Second Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Temperature 102.2°F (39.0°C) or more for fevers.</description>
        <time_frame>From Day 0 to Day 6 after the second vaccination</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Solicited Systemic AEs After the Second Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for. Grade 3 solicited AE definitions: Prevented normal daily activities; Temperature 102.2°F (39.0°C) or more for fevers.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3"/>
                    <measurement group_id="O2" value="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6"/>
                    <measurement group_id="O2" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise/feeling generally unwell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise/feeling generally unwell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any muscle ache (myalgia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 muscle ache (myalgia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Solicited Systemic AEs After the Second Vaccination</title>
        <description>Solicited AEs included AEs that were specifically sought for.</description>
        <time_frame>From Day 0 to Day 6 after the second vaccination and up to Day 20 after the second vaccination if AE is ongoing at Day 7</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Systemic AEs After the Second Vaccination</title>
          <description>Solicited AEs included AEs that were specifically sought for.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="0.403"/>
                    <measurement group_id="O2" value="1.58" spread="1.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise/feeling generally unwell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.929"/>
                    <measurement group_id="O2" value="2.10" spread="1.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle ache (myalgia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="2.275"/>
                    <measurement group_id="O2" value="2.06" spread="1.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.414"/>
                    <measurement group_id="O2" value="1.29" spread="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00">Only 1 participant experienced chills so the standard deviation cannot be derived.</measurement>
                    <measurement group_id="O2" value="1.25" spread="0.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in the CSL425 (15 mcg) group experienced vomiting after the second vaccination.</measurement>
                    <measurement group_id="O2" value="NA">No participants in the CSL425 (30 mcg) group experienced vomiting after the second vaccination.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in the CSL425 (15 mcg) group experienced fever after the second vaccination.</measurement>
                    <measurement group_id="O2" value="1.33" spread="0.577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and New Onset of Chronic Illnesses (NOCIs)</title>
        <description>An AESI was defined as an AE for which the association with seasonal influenza vaccine was unclear. A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (eg, diabetes, asthma).</description>
        <time_frame>Up to 180 days after the last vaccination</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and New Onset of Chronic Illnesses (NOCIs)</title>
          <description>An AESI was defined as an AE for which the association with seasonal influenza vaccine was unclear. A NOCI was defined as the diagnosis of a new medical condition that was chronic in nature, including those potentially controllable by medication (eg, diabetes, asthma).</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related NOCI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Intensity of Unsolicited AEs</title>
        <description>Unsolicited AEs included AEs other than those specifically sought for.
The grading definitions were:
Mild (Grade 1): Symptoms were easily tolerated and did not interfere with daily activities.
Moderate (Grade 2): Enough discomfort to cause some interference with daily activities.
Severe (Grade 3): Incapacitating, with inability to work or do usual activities.</description>
        <time_frame>From Day 0 to Day 20 after vaccination; up to 180 days after the last vaccination for SAEs, AESIs, and NOCIs</time_frame>
        <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>CSL425 (15 mcg)</title>
            <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
          <group group_id="O2">
            <title>CSL425 (30 mcg)</title>
            <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Intensity of Unsolicited AEs</title>
          <description>Unsolicited AEs included AEs other than those specifically sought for.
The grading definitions were:
Mild (Grade 1): Symptoms were easily tolerated and did not interfere with daily activities.
Moderate (Grade 2): Enough discomfort to cause some interference with daily activities.
Severe (Grade 3): Incapacitating, with inability to work or do usual activities.</description>
          <population>The Safety Population comprised all participants who received at least one dose of the vaccine and provided follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All unsolicited AEs after the first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 unsolicited AEs after the first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 unsolicited AEs after the first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                    <measurement group_id="O2" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 unsolicited AEs after the first dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All unsolicited AEs after the second dose (n=119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total unsolicited AEs after doses 1 &amp; 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2"/>
                    <measurement group_id="O2" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total grade 1 unsolicited AEs after doses 1 &amp; 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total grade 2 unsolicited AEs after doses 1 &amp; 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total grade 3 unsolicited AEs after doses 1 &amp; 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For SAEs: up to 180 days after the last vaccination. For Other AEs: solicited AEs: from Day 0 to Day 6 after each vaccination; unsolicited AEs: from Day 0 to Day 20 after each vaccination; up to 180 days after the last vaccination for AESIs and NOCIs.</time_frame>
      <desc>Unsolicited AEs presented in the organ system &quot;General disorders&quot; with a footnote of &quot;MedDRA 12.1&quot;, were collected under the MedDRA System Organ Class (SOC) 'General disorders and administration site conditions'. Solicited AEs are presented in the organ system &quot;General disorders&quot; and were not collected under the MedDRA SOC.</desc>
      <group_list>
        <group group_id="E1">
          <title>CSL425 (15 mcg)</title>
          <description>15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
        </group>
        <group group_id="E2">
          <title>CSL425 (30 mcg)</title>
          <description>30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pain at injection site</sub_title>
                <counts group_id="E1" events="39" subjects_affected="31" subjects_at_risk="120"/>
                <counts group_id="E2" events="47" subjects_affected="36" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Redness at injection site</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Swelling/Induration at injection site</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Tenderness at injection site</sub_title>
                <counts group_id="E1" events="63" subjects_affected="47" subjects_at_risk="120"/>
                <counts group_id="E2" events="99" subjects_affected="66" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Bruising at injection site</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="55" subjects_affected="42" subjects_at_risk="120"/>
                <counts group_id="E2" events="87" subjects_affected="52" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Malaise/feeling generally unwell</sub_title>
                <counts group_id="E1" events="32" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E2" events="55" subjects_affected="37" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Muscle ache (myalgia)</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="120"/>
                <counts group_id="E2" events="43" subjects_affected="29" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" events="18" subjects_affected="12" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="35" subjects_affected="20" subjects_at_risk="120"/>
                <counts group_id="E2" events="44" subjects_affected="25" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>CSL Limited</organization>
      <phone>Use email contact</phone>
      <email>csl.clinicaltrials@csl.com.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

